Liebe HTA-Interessierte,

wir freuen uns, Sie darauf hinweisen zu dürfen, dass folgende neue Berichte (online) veröffentlicht wurden:

Policy Briefs:

• Stuhl-DNA-Test zur Früherkennung von Darmkrebs. AIHTA Policy Brief 011.

Oncology Factsheets:

• Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with Waldenström's Macroglobulinaemia (WM). Oncology Fact Sheet Nr. 60.
• Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 61.
• Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Oncology Fact Sheet Nr. 62.
• Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma. Oncology Fact Sheet Nr. 63.
• Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC). Oncology Fact Sheet Nr. 64.

Mit freundlichen Grüßen
Ozren Sehic
______________________________________________________________________________

Ozren Sehic, B.A.
Assistenz der Geschäftsführung und Wissenschaftskommunikation
Austrian Institute for Health Technology Assessment
Garnisongasse 7/20, 1090 Vienna
Tel: +43 (0) 1 236 81 19-23
Webseite